Anti-platelet agregation: what did we learn from the evidence?
Hyperglycemia and insulin resistance, characteristics of patients with type 2 diabetes mellitus (T2D), produce platelet and endothelial alterations, increasing the risk of thrombotic events. The efficacy and benefit of antiplatelet therapy are well established in patients with atherosclerotic cardio...
Main Author: | Augusto Lavalle Cobo |
---|---|
Format: | Article |
Language: | Spanish |
Published: |
Sello Editorial Lugones
2022-09-01
|
Series: | Revista de la Sociedad Argentina de Diabetes |
Subjects: | |
Online Access: | https://revistasad.com/index.php/diabetes/article/view/595 |
Similar Items
-
Ativação plaquetária na esclerose sistêmica e alternativas metodológicas para sua avaliação Platelet activation in systemic sclerosis and methodological options to its assessment
by: Paulo Sergio Massabki, et al.
Published: (2004-02-01) -
Impacto del tiempo de intervención en pacientes con IAMSEST: diseño del estudio IMPACT-TIMING-GO
by: Felipe Díez-Delhoyo, et al.
Published: (2023-02-01) -
Uso clínico de drogas antiplaquetarias
by: Diego Mezzano A.
Published: (2017-05-01) -
Respuesta de los sujetos con hipertensión arterial a los fármacos antiagregantes plaquetarios
by: Nancy Irene Frutos Andreu, et al.
Published: (2020-05-01) -
In vitro effect of the herbicide glyphosate on human blood platelet aggregation and coagulation Efeito in vitro do herbicida glifosato na agregação plaquetária e coagulação sanguínea em humanos
by: Teresinha de Jesus C. Neiva, et al.
Published: (2010-01-01)